TriangleCarboplatin (NCT04332367)
Carboplatin trial for Non-small Cell Lung Cancer (NCT04332367). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced nonsquamous non-small-cell lung cancer progressing after at least eighteen weeks of maintenance pemetrexed, pembrolizumab, or both. Four to six prior cycles of pemetrexed, carboplatin, and pembrolizumab are required. Targetable driver mutations exclude entry.
The idea: carboplatin and paclitaxel chemotherapy accompany ramucirumab, which blocks blood-vessel growth signaling through VEGFR2. Infusions repeat every three weeks, with paclitaxel on days one and eight. Researchers assess tumor shrinkage and safety.
This phase 2 study plans 59 patients. Melina Marmarelis leads at Penn, Philadelphia, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.